According to the company, it will now offer testing outlined in OECD 427 (in vivo studies in rodent models) and OECD 428 (in vitro studies using human and animal skin).
Bill Reifenrath, Ph.D., has also joined EAG as a senior scientific advisor, bringing with him his knowledge in dermal absorption. Reifenrath will be located at the company’s Hercules, California location.
“Pharmaceutical, consumer products, agrochemical and other chemical industries have a critical need for high-quality scientific partners who understand the regulatory guidelines and can execute complex study designs,” EAG’s CEO, Siddhartha Kadia, Ph.D. said in the company’s release.
“These new dermal capabilities strengthen EAG’s offering to companies required to assess their products’ potential effects on human health and the environment in accordance with OECD Guidelines.”
Additionally, late last year, EAG added to its environmental capabilities with a 33,000-square-foot expansion at its Easton, Maryland facility. The expansion added space for dedicated laboratories and equipment to support GLP-compliant ecotoxicology, environmental fate, metabolism, and other testing services.
Prior to this expansion, EAG Laboratories combined 11 of its brands, including ABC Laboratories, to reside under a single company continues to expand its capabilities to support the biopharmaceutical market.